Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616001000493
Ethics application status
Approved
Date submitted
22/07/2016
Date registered
28/07/2016
Date last updated
13/02/2024
Date data sharing statement initially provided
16/11/2018
Date results provided
15/09/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
A study to evaluate the feasibility of performing genomic testing of rare cancers to match the cancer to treatment. GeNOmic MatchINg treATment fOr Rare cancers (NOMINATOR).
Scientific title
A national multicentre clinical trial to assess the feasibility of performing genomic testing of rare cancers to match the cancer to treatment.
Secondary ID [1] 289741 0
Nil known
Universal Trial Number (UTN)
Trial acronym
GeNOmic MatchINg treATment fOr Rare cancers (NOMINATOR).
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rare cancer. 299585 0
Condition category
Condition code
Cancer 299555 299555 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Eligible participants will consent to the collection of tumour tissue and up to three blood samples. If clinically indicated, a tumour biopsy will be performed for some participants, or an archival sample of the tumour will be retrieved for a gene sequencing test. The study will use gene sequencing to identify genetic mutations present in a person’s cancer cells (a cancer genomic profile). Following analysis of the samples, each case will be discussed in a Molecular Tumour Board with the involvement of a range of relevant experts, including scientists, bioinformaticians, specialists in genetics and oncologists. The Molecular Tumour Board will comment on validated or promising treatments as a result of the genomic analysis - these will not be limited to locally available or PBS funded medications. Recommendations are non-prescriptive and the patient’s treating oncologist will decide on treatment options. Results of the gene sequencing test will be sent to the participant’s treating oncologist.

Participants may elect to receive the results of the gene sequencing test from their treating oncologist, or to attend a visit at the hospital. After the results have been discussed, participants will be asked to fill out questionnaires that will ask about participation in the study, and whether or not they feel that the gene sequencing test has been helpful in terms of choosing future treatment options.

Participants will be asked to:
*attend a screening visit to have some tests done to assess whether or not the NOMINATOR study is suitable for them;
*attend one or more hospital visits to collect blood and tumour samples and complete a baseline questionnaire;
*attend an optional hospital visit to receive the results of the gene sequencing test and to complete a questionnaire;
*attend up to two more visits to the hospital for blood tests which will be used to track circulating tumour DNA which may help identify response to treatment (this analysis is exploratory).
*complete questionnaires at 6, 12 and at 24 months (participants may complete questionnaires during hospital visits or by mail).
Intervention code [1] 295379 0
Diagnosis / Prognosis
Comparator / control treatment
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 299033 0
To determine the proportion of rare cancer cases where a potentially actionable aberration (pathogenic mutation vs no mutation vs possible mutation, ie level of evidence reported) is identified following analysis of genetic sequencing.
Timepoint [1] 299033 0
Level of evidence reported will be assessed by the Molecular Tumour Board following genetic sequencing of each participant’s tumour biopsy sample..
Secondary outcome [1] 325926 0
The proportion of rare cancer cases for which a relevant drug or clinical trial is available (regardless of access).
Timepoint [1] 325926 0
Determined by Molecular Tumour Board review/recommendation and search of clinical trial registries. Medical record data will also be collected and assessed after the last participant is enrolled.
Secondary outcome [2] 325927 0
The proportion of cases for which a relevant drug or trial is available in the relevant Australian state.
Timepoint [2] 325927 0
Determined by Molecular Tumour Board review/recommendation and search of clinical trial registries. Data from investigators, recruitment and medical records will also be collected and assessed after the last participant is enrolled.
Secondary outcome [3] 325928 0
The number of cases in which a relevant trial or drug is accessed.
Timepoint [3] 325928 0
Data will be collected from investigators and medical records and assessed after the last participant is enrolled.
Secondary outcome [4] 325929 0
The proportion of cases where genetic sequencing testing impacted on patient management.
Timepoint [4] 325929 0
Data will be collected from investigators and medical records and assessed after the last participant is enrolled.
Secondary outcome [5] 325930 0
The proportion of cases where molecular testing impacted on understanding of etiology of the patient’s rare cancer, including a change in tumour diagnosis.
Timepoint [5] 325930 0
Data will be collected from investigators and medical records and assessed after the last participant is enrolled.
Secondary outcome [6] 325931 0
The number of suitable patients across multiple sites.
Timepoint [6] 325931 0
Recruitment data will be collected and assessed after the last participant is enrolled.
Secondary outcome [7] 325932 0
Assess psychosocial well-being, relevant for the uncertainty of having a rare cancer using the validated Impact of Event Scale 6 Questionnaire.
Timepoint [7] 325932 0
Data will collected at baseline, after the results of genomic sequencing report have been received, and at the 6 month, 12 month and 24 month time-points for each participant. Data will be analysed after the last participant is registered.
Secondary outcome [8] 326040 0
Identify the response to treatment, if documented.
Timepoint [8] 326040 0
Medical record data will be collected and assessed after the last participant is enrolled.
Secondary outcome [9] 326041 0
Identify the proportion of patients approached who consent to the study.
Timepoint [9] 326041 0
Recruitment data will be collected and assessed after the last participant is enrolled.

Eligibility
Key inclusion criteria
* Patients aged over 18 years, with signed informed consent and ability to comply with protocol requirements
* Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Patients with a life expectance of >12 weeks
* Access to tumour tissue is available from core biopsy or surgical resection from a disease site
* Histologically confirmed rare histopathology diagnosis according to the RARECARE group definition
* Malignancy where little evidence-based care or standard of care therapies exist
* Tumour type associated with a poor outcome
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients who are unable, or unwilling to consent to the study.
* Patients who have a concurrent active malignancy other than adequately treated non-melanomatous skin cancer, early prostatic adenocarcinoma treated with curative intent or non-invasive carcinoma / in-situ neoplasm of the cervix or breast. Patients with a previous history of malignancy will be eligible provided they have been disease-free for >5 years.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
This is an exploratory study which aims to provide a reasonable estimate of the variability of rare tumour analysis that we are likely to see in subsequent larger studies. A minimum for statistical significance has not been set and the analysis will be descriptive.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
30/07/2017
Actual
17/07/2017
Date of last participant enrolment
Anticipated
31/12/2019
Actual
29/11/2019
Date of last data collection
Anticipated
29/11/2021
Actual
31/12/2021
Sample size
Target
100
Accrual to date
Final
100
Recruitment in Australia
Recruitment state(s)
QLD,SA,WA,VIC
Recruitment hospital [1] 6238 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 6239 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [3] 6240 0
St John of God Hospital, Subiaco - Subiaco
Recruitment hospital [4] 8669 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 13659 0
5000 - Adelaide
Recruitment postcode(s) [2] 13660 0
4029 - Herston
Recruitment postcode(s) [3] 13661 0
6008 - Subiaco
Recruitment postcode(s) [4] 16781 0
3000 - Melbourne

Funding & Sponsors
Funding source category [1] 294122 0
Charities/Societies/Foundations
Name [1] 294122 0
Stafford Fox Medical Research Foundation
Country [1] 294122 0
Australia
Funding source category [2] 294123 0
Other Collaborative groups
Name [2] 294123 0
Melbourne Genomics Health Alliance
Country [2] 294123 0
Australia
Primary sponsor type
Hospital
Name
Melbourne Health
Address
Melbourne Health Office for Research
PO Royal Melbourne Hospital
Parkville Victoria 3050
Country
Australia
Secondary sponsor category [1] 292950 0
None
Name [1] 292950 0
Address [1] 292950 0
Country [1] 292950 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295528 0
Melbourne Health Human Research Ethics Committee
Ethics committee address [1] 295528 0
Ethics committee country [1] 295528 0
Australia
Date submitted for ethics approval [1] 295528 0
29/09/2015
Approval date [1] 295528 0
14/12/2015
Ethics approval number [1] 295528 0
HREC/15/MH/310

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 67638 0
A/Prof Clare Scott
Address 67638 0
Walter and Eliza Hall Institute of Medical Research
Walter and Eliza Hall Institute
1G Royal Parade
Parkville Victoria 3052
Australia
Country 67638 0
Australia
Phone 67638 0
+61 3 9345 2498
Fax 67638 0
+61 3 9347 0852
Email 67638 0
nominator@mh.org.au
Contact person for public queries
Name 67639 0
Damien Kee
Address 67639 0
Walter and Eliza Hall Institute
1G Royal Parade
Parkville Victoria 3052
Australia
Country 67639 0
Australia
Phone 67639 0
+61 3 93452981
Fax 67639 0
Email 67639 0
nominator@mh.org.au
Contact person for scientific queries
Name 67640 0
Damien Kee
Address 67640 0
Walter and Eliza Hall Institute
1G Royal Parade
Parkville Victoria 3052
Australia
Country 67640 0
Australia
Phone 67640 0
+61 3 93452981
Fax 67640 0
Email 67640 0
nominator@mh.org.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Further discussion required with trial principal investigator.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.